• Citer

An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer.

par Piccart-Gebhart, Martine ;Bruning, Peter;Gamucci, T;Klijn, J G;Roy, J A;Awada, Ahmad ;Kusenda, Zlatko;Van Vreckem, Ann;Paridaens, R.
Référence Seminars in oncology, 23, 5 Suppl 11, page (11-15)
Publication Publié, 1996-10

Article révisé par les pairs

• Détails
• Contenu

Résumé :

The activity of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in advanced breast cancer patients who have failed doxorubicin treatment is well established, but the optimal sequence between these two important agents remains to be determined. The European Organization for Research and Treatment of Cancer therefore designed a prospective randomized clinical trial in which patients not exposed to anthracyclines in the adjuvant setting received either first-line paclitaxel, given as a 3-hour infusion at a dose of 200 mg/m2 followed at the time of disease progression by second-line doxorubicin, given as a bolus injection at a dose of 75 mg/m2 or the reverse sequence. The target accrual is 330 patients. Interim results on 207 evaluable patients of 289 randomized are presented.